Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Directs patients’ immune system to kill multiple myeloma cells

https://www.eurekalert.org/news-releases/973924

"The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells—white blood cells that can be enlisted to fight off diseases—to kill multiple myeloma cells. The researchers described this strategy as 'bringing your army right to the enemy.'"

#science